Kornowski shifts gears at Boston Pharma, sets NASH program as top priority
Ex-Roche exec refines focus, decides what to keep and commercialize vs. what to partner out
Seven years after Gurnet Point launched Boston Pharma, new CEO Sophie Kornowski is leading a transition away from the company’s prior model of bringing in-licensed assets to proof of concept and then partnering them out. Now, the company has refined its focus to three disease areas and prioritized four assets, any of which it could take to market itself — and is seeking to broaden its investor base with a nine-digit round of funding to support development of a late-stage asset.
Kornowski told BioCentury that Boston Pharmaceuticals Inc. is emphasizing a few well-differentiated programs it intends to advance in the near term, led by a treatment it believes can be “best in class and best in disease” for non-alcoholic steatohepatitis. The team is aiming to develop treatments in areas in which it has expertise, where it believes it can offer a large benefit to patients...